Selvita

Historical price data

Selvita is a mission-driven biotech bridging scientific innovation and clinical development through a dual model of integrated CRO services and proprietary drug R&D. Founded in 2007 and publicly listed in Warsaw, the company has matured into a Central European leader, leveraging its scientific platform to generate service revenue and build value in its oncology pipeline. Its strategy focuses on operational excellence in its service division to fund and de-risk the advancement of its internal therapeutic candidates, targeting significant unmet medical needs in cancer.

An integrated, end-to-end drug discovery and development platform spanning medicinal/computational chemistry, biology, DMPK, protein sciences, preformulation, analytical development, and GLP/GMP regulatory services, applied to both client projects and proprietary pipeline R&D.

Competes with global CRO giants and specialized discovery firms on service quality, integrated offerings, and cost-competitiveness. As a drug developer, faces the vast, high-risk competitive field of oncology biotechs, differentiating through its efficient, platform-driven R&D approach.